Sufenidone-Guangzhou-JOYO-Pharma
Alternative Names: SC-1011Latest Information Update: 24 Nov 2023
At a glance
- Originator Guangzhou JOYO Pharma
- Class Antifibrotics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Idiopathic pulmonary fibrosis
Most Recent Events
- 15 Nov 2023 Phase-II/III clinical trials in Idiopathic pulmonary fibrosis in China (PO) (NCT06125327)
- 14 Jan 2023 Guangzhou JOYO Pharma completes a phase I trial in Idiopathic pulmonary fibrosis (In volunteers) in China (PO) ( NCT06135363)